These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3539147)

  • 1. Structure-function relationships of shortened [LeuB25]insulins, semisynthetic analogues of a mutant human insulin.
    Fischer WH; Saunders D; Brandenburg D; Diaconescu C; Wollmer A; Dodson G; De Meyts P; Zahn H
    Biol Chem Hoppe Seyler; 1986 Sep; 367(9):999-1006. PubMed ID: 3539147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A shortened insulin with full in vitro potency.
    Fischer WH; Saunders D; Brandenburg D; Wollmer A; Zahn H
    Biol Chem Hoppe Seyler; 1985 May; 366(5):521-5. PubMed ID: 3890892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semisynthesis and biological activity of porcine [LeuB24]insulin and [LeuB25]insulin.
    Tager H; Thomas N; Assoian R; Rubenstein A; Saekow M; Olefsky J; Kaiser ET
    Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3181-5. PubMed ID: 6997872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function relationships of des-(B26-B30)-insulin.
    Spoden M; Gattner HG; Zahn H; Brandenburg D
    Int J Pept Protein Res; 1995; 46(3-4):221-7. PubMed ID: 8537175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain.
    Záková L; Barth T; Jirácek J; Barthová J; Zórad S
    Biochemistry; 2004 Mar; 43(8):2323-31. PubMed ID: 14979729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shortened insulin with enhanced in vitro potency.
    Casaretto M; Spoden M; Diaconescu C; Gattner HG; Zahn H; Brandenburg D; Wollmer A
    Biol Chem Hoppe Seyler; 1987 Jun; 368(6):709-16. PubMed ID: 3304338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine.
    Lenz V; Gattner HG; Sievert D; Wollmer A; Engels M; Höcker H
    Biol Chem Hoppe Seyler; 1991 Jul; 372(7):495-504. PubMed ID: 1930732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo metabolic activity of des-(B26-B30)-insulin-B25-amide and related analogues in the rat.
    Stümpel F; Hartmann H; Brandenburg D; Creutzfeldt W
    Diabetes Res Clin Pract; 1990 Jul; 9(3):257-64. PubMed ID: 2226126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [LeuB24]- and [LeuB25]insulins are not antagonists of lipogenesis in adipocytes.
    Diaconescu C; Saunders D; Gattner HG; Brandenburg D
    Hoppe Seylers Z Physiol Chem; 1982 Feb; 363(2):187-92. PubMed ID: 7037593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.
    Nakagawa SH; Tager HS
    J Biol Chem; 1986 Jun; 261(16):7332-41. PubMed ID: 3519607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions.
    Shoelson SE; Lu ZX; Parlautan L; Lynch CS; Weiss MA
    Biochemistry; 1992 Feb; 31(6):1757-67. PubMed ID: 1737029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semisynthesis and biological properties of the [B24-leucine]-, [B25-leucine[- and [B24-leucine, B25-leucine]-analogues of human insulin.
    Inouye K; Watanabe K; Tochino Y; Kanaya T; Kobayashi M; Shigeta Y
    Experientia; 1981; 37(8):811-3. PubMed ID: 7026270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme-assisted semisynthesis of shortened B26-modified insulins.
    Sievert D; Gattner HG; Lenz V; Höcker H
    Biomed Biochim Acta; 1991; 50(10-11):S197-200. PubMed ID: 1820045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semisynthetic insulin analogues modified in positions B24, B25 and B29.
    Svoboda I; Brandenburg D; Barth T; Gattner HG; Jirácek J; Velek J; Bláha I; Ubik K; Kasicka V; Pospísek J
    Biol Chem Hoppe Seyler; 1994 Jun; 375(6):373-8. PubMed ID: 7980868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two mutant forms of human insulin. Structural consequences of the substitution of invariant B24- or B25-phenylalanine by leucine.
    Wollmer A; Strassburger W; Glatter U; Dodson GG; McCall M; Gattner HG; Danho W; Brandenburg D; Rittel W
    Hoppe Seylers Z Physiol Chem; 1981 Jun; 362(6):581-91. PubMed ID: 7024084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and biological properties of [LeuB24, LeuB25]human insulin.
    Jonczyk A; Keefer LM; Naithani VK; Gattner HG; De Meyts P; Zahn H
    Hoppe Seylers Z Physiol Chem; 1981 May; 362(5):557-61. PubMed ID: 7019034
    [No Abstract]   [Full Text] [Related]  

  • 17. An insulin analogue possessing higher in vitro biological activity than receptor binding affinity. [21-Proline-B]insulin.
    Schwartz GP; Burke GT; Chanley JD; Katsoyannis PG
    Biochemistry; 1983 Sep; 22(19):4561-7. PubMed ID: 6354263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone.
    Leyer S; Gattner HG; Leithäuser M; Brandenburg D; Wollmer A; Höcker H
    Int J Pept Protein Res; 1995 Nov; 46(5):397-407. PubMed ID: 8567184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of binding of a low affinity, noncooperative insulin [( LeuB25]insulin) to IM-9 lymphocytes.
    Green A; Frank BH; Rubenstein A; Tager H; Olefsky JM
    Endocrinology; 1983 Dec; 113(6):1963-71. PubMed ID: 6357764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of the phenylalanine B25 side chain during insulin-receptor and insulin-insulin interactions.
    Mirmira RG; Tager HS
    Biochemistry; 1991 Aug; 30(33):8222-9. PubMed ID: 1868095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.